Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Growth in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 12,400 shares, an increase of 134.0% from the December 15th total of 5,300 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 49,800 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, HC Wainwright cut their target price on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday.

Barinthus Biotherapeutics Stock Up 7.7 %

BRNS stock traded up $0.07 during midday trading on Wednesday, hitting $1.02. 123,674 shares of the company traded hands, compared to its average volume of 48,586. Barinthus Biotherapeutics has a twelve month low of $0.80 and a twelve month high of $4.16. The stock has a market capitalization of $41.03 million, a price-to-earnings ratio of -0.68 and a beta of -0.81. The business has a 50 day simple moving average of $1.07 and a 200-day simple moving average of $1.24.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same quarter in the previous year, the firm earned ($0.37) EPS. Equities research analysts forecast that Barinthus Biotherapeutics will post -1.52 EPS for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.